Top

Published in:

Open Access 01-11-2020 | Mastectomy | Epidemiology

Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy

Authors: Fabian Riedel, Joerg Heil, Manuel Feisst, Mareike Moderow, Alexandra von Au, Christoph Domschke, Laura Michel, Benedikt Schaefgen, Michael Golatta, André Hennigs

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Purpose

In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1–T2 cN0 early breast cancer and 1–2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3–T4) tumor stages and/or underwent mastectomy but otherwise met the ACOSOG Z0011 eligibility criteria. Aim of this study is to determine cALND time trends and non-sentinel axillary metastases (NSAM) rates to estimate occult axillary tumor burden.

Methods

Data were included from patients treated in 179 German breast cancer centers between 2008 and 2015. Time-trend rates were analyzed for cALND of patients with T3–T4 tumors separated for BCT and mastectomy and regarding presence of axillary macrometastases or micrometastases.

Results

Data were available for 188,909 patients, of whom 19,009 were identified with 1–2 positive SLN. Those 19,009 patients were separated into 4 cohorts: (1) Patients with T1–T2 tumors receiving BCT (ACOSOG Z0011 eligible; n = 13,741), (2) T1–T2 with mastectomy (n = 4093), (3) T3–T4 with BCT (n = 269), (4) T3–T4 with mastectomy (n = 906). Among patients with T3–T4 tumors, cALND rates declined from 2008 to 2015: from 88.2 to 62.6% for patients receiving mastectomy and from 96.6 to 58.1% in patients receiving BCT. Overall rates for any NSAM after cALND for cohorts 1–4 were 33.4%, 42.3%, 46.9%, 58.8%, respectively.

Conclusions

The cALND rates have decreased substantially in routine care in patients with ‘extended’ ACOSOG Z0011 eligibility criteria. Axillary tumor burden is higher in these patients than in the ACOSOG Z0011 trial.

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373(4):307–316CrossRef

Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2880CrossRef

Riedel F, Heil J, Golatta M, Schaefgen B, Hug S, Schott S et al (2019) Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. Arch Gynecol Obstet 299(4):1043–1053CrossRef

Schwartz GF, Giuliano AE, Veronesi U (2002) Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia Pennsylvania. Cancer 94(10):2542–2551CrossRef

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252(3):426–433

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918–926CrossRef

Maguire A, Brogi E (2016) Sentinel lymph nodes for breast carcinoma: a paradigm shift. Arch Pathol Lab Med 140(8):791–798CrossRef

Guth U, Myrick ME, Viehl CT, Schmid SM, Obermann EC, Weber WP (2012) The post ACOSOG Z0011 era: does our new understanding of breast cancer really change clinical practice? Eur J Surg Oncol 38(8):645–650CrossRef

Morrow M, Giuliano AE (2011) To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol 18(9):2413–2415CrossRef

10.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305CrossRef

11.

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M et al (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19(10):1385–1393CrossRef

12.

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRef

13.

Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E et al (2017) Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43(4):672–679CrossRef

14.

Riedel F, Heil J, Feisst M, Rezai M, Moderow M, Sohn C et al (2019) Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. Breast Cancer Res Treat 177(2):457–467CrossRef

15.

Ditsch N, Untch M, Thill M, Muller V, Janni W, Albert US et al (2019) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019. Breast Care (Basel) 14(4):224–245CrossRef

16.

Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U et al (2019) Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat 173(2):429–438CrossRef

17.

Morrow M, Jagsi R, McLeod MC, Shumway D, Katz SJ (2018) Surgeon attitudes toward the omission of axillary dissection in early breast cancer. JAMA Oncol 4(11):1511–1516CrossRef

18.

Bhatt NR, Boland MR, McGovern R, Lal A, Tormey S, Lowery AJ et al (2018) Upper limb lymphedema in breast cancer patients in the era of Z0011, sentinel lymph node biopsy and breast conservation. Ir J Med Sci 187(2):327–331CrossRef

19.

Fillion MM, Glass KE, Hayek J, Wehr A, Phillips G, Terando A et al (2017) healthcare costs reduced after incorporating the results of the American College of Surgeons Oncology Group Z0011 trial into clinical practice. Breast J 23(3):275–281CrossRef

20.

Cody HS (2017) Extending ACOSOG Z0011 to encompass mastectomy: what happens without RT? Ann Surg Oncol 24(3):621–623CrossRef

21.

Hennigs A, Riedel F, Feisst M, Kopke M, Rezai M, Nitz U et al (2019) Evolution of the use of completion axillary lymph node dissection in patients with T1/2N0M0 breast cancer and tumour-involved sentinel lymph nodes undergoing mastectomy: a Cohort study. Ann Surg Oncol 26(8):2435–2443CrossRef

22.

Poodt IGM, Spronk PER, Vugts G, van Dalen T, Peeters M, Rots ML et al (2018) Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: a dutch population-based study in the ACOSOG-Z0011 and AMAROS Era. Ann Surg 268(6):1084–1090CrossRef

23.

Brucker SY, Schumacher C, Sohn C, Rezai M, Bamberg M, Wallwiener D (2008) Onkologische Qualitätssicherung am Beispiel des Mammakarzinom-Benchmarkings interdisziplinärer Brustzentren. Senologie-Zeitschrift für Mammadiagnostik und -therapie 5(03):143–155CrossRef

24.

Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I et al (2013) Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg 216(1):105–113CrossRef

25.

Kenny TC, Dove J, Shabahang M, Woll N, Hunsinger M, Morgan A et al (2016) Widespread implications of ACOSOG Z0011: effect on total mastectomy patients. Am Surg 82(1):53–58CrossRef

26.

Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ (2015) Impact of the American College of Surgeons Oncology Group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer. J Am Coll Surg 221(1):71–81CrossRef

27.

Wockel A, Festl J, Stuber T, Brust K, Krockenberger M, Heuschmann PU et al (2018) Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. guideline of the DGGG and the DKG (S3-Level, AWMF registry number 032/045OL, December 2017): part 2 WITH recommendations for the therapy of primary, recurrent and advanced breast cancer. Geburtshilfe Frauenheilkd. 78(11):1056–1088CrossRef

28.

Fu Y, Chung D, Cao MA, Apple S, Chang H (2014) Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? Ann Surg Oncol 21(13):4109–4123CrossRef

29.

van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, Strobbe LJ, Boersma LJ et al (2015) The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013–07). BMC Cancer 15:610CrossRef

30.

Goyal A, Dodwell D (2015) POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol (R Coll Radiol) 27(12):692–695CrossRef

31.

de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L et al (2017) Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer 17(1):379CrossRef

32.

Poodt IGM, Schipper RJ, Vugts G, Woensdregt K, van der Sangen M, Voogd AC et al (2018) The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. Eur J Surg Oncol 44(11):1714–1719CrossRef

33.

Caretta-Weyer H, Greenberg CG, Wilke LG, Weiss J, LoConte NK, Decker M et al (2013) Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis. Ann Surg Oncol 20(13):4145–4152CrossRef

34.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553CrossRef

35.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933CrossRef

36.

Majid S, Ryden L, Manjer J (2019) Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases. BMC Cancer 19(1):626CrossRef

37.

Wang XY, Wang JT, Guo T, Kong XY, Chen L, Zhai J et al (2019) Risk factors and a predictive nomogram for non-sentinel lymph node metastases in Chinese breast cancer patients with one or two sentinel lymph node macrometastases and mastectomy. Curr Oncol 26(2):e210–e215

38.

Poodt IGM, Rots ML, Vugts G, van Dalen T, Kuijer A, Vriens B et al (2018) The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study. Eur J Surg Oncol 44(8):1151–1156CrossRef

39.

Barrio AV, Downs-Canner S, Edelweiss M, Van Zee KJ, Cody HS 3rd, Gemignani ML et al (2019) Microscopic extracapsular extension in sentinel lymph nodes does not mandate axillary dissection in Z0011-eligible patients. Ann Surg Oncol. (epub ahead of print).

40.

Pilewskie M, Morrow M (2017) Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol 3(4):549–555CrossRef

Title: Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy
Authors: Fabian Riedel
Joerg Heil
Manuel Feisst
Mareike Moderow
Alexandra von Au
Christoph Domschke
Laura Michel
Benedikt Schaefgen
Michael Golatta
André Hennigs
Publication date: 01-11-2020
Publisher: Springer US
Keywords: Mastectomy
Metastasis
Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05876-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer

Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type

Increasing accrual of minority patients in breast cancer clinical trials

Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer

BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer

Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer